Ariceum Therapeutics

Ariceum Therapeutics is a private biotechnology company based in Berlin, Germany, dedicated to the development of novel targeted radiopharmaceuticals for the diagnosis and treatment of aggressive, hard-to-treat cancers [2,5,6]. The company utilizes a systemic targeted radiotherapy (STR) approach, designing molecules that specifically bind to tumor cell structures—such as the somatostatin type 2 receptor—to deliver therapeutic doses of radiation with high precision [1,4]. By coupling radionuclides to these targeting molecules, Ariceum aims to minimize exposure to healthy tissues and reduce side effects compared to traditional systemic treatments [4]. Its pipeline includes programs like satoreotide (SSO110) and ATT001, which are being investigated for indications such as small cell lung cancer, Merkel cell carcinoma, and recurrent glioblastoma [2,3,6].

These therapies are designed as theranostic pairs, providing both a mechanism for visualizing tumors and a targeted radionuclide treatment, offering a solution for patients with limited therapeutic options and poor prognoses [2,6]. Founded in 2021, the company has secured significant venture capital funding and established strategic supply and research collaborations, including partnerships with UCB Pharma and various medical isotope providers, to advance its clinical-stage pipeline [2,5,6]. The company operates internationally across Europe, North America, and Australia, focusing on innovating radiopharmaceutical technology to improve patient outcomes in oncology [2,6,8].